151 related articles for article (PubMed ID: 19755676)
1. TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas.
Young RM; Polsky A; Refaeli Y
Blood; 2009 Dec; 114(24):5016-23. PubMed ID: 19755676
[TBL] [Abstract][Full Text] [Related]
2. Targeted disruption of TC-PTP in the proliferative compartment augments STAT3 and AKT signaling and skin tumor development.
Lee H; Kim M; Baek M; Morales LD; Jang IS; Slaga TJ; DiGiovanni J; Kim DJ
Sci Rep; 2017 Mar; 7():45077. PubMed ID: 28322331
[TBL] [Abstract][Full Text] [Related]
3. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
4. Activation of T-cell protein-tyrosine phosphatase suppresses keratinocyte survival and proliferation following UVB irradiation.
Lee H; Morales LD; Slaga TJ; Kim DJ
J Biol Chem; 2015 Jan; 290(1):13-24. PubMed ID: 25406309
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.
den Hollander J; Rimpi S; Doherty JR; Rudelius M; Buck A; Hoellein A; Kremer M; Graf N; Scheerer M; Hall MA; Goga A; von Bubnoff N; Duyster J; Peschel C; Cleveland JL; Nilsson JA; Keller U
Blood; 2010 Sep; 116(9):1498-505. PubMed ID: 20519624
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of TC-PTP in murine epidermis attenuates skin tumor formation.
Kim M; Morales LD; Lee CJ; Olivarez SA; Kim WJ; Hernandez J; Mummidi S; Jenkinson C; Tsin AT; Jang IS; Slaga TJ; Kim DJ
Oncogene; 2020 May; 39(21):4241-4256. PubMed ID: 32286519
[TBL] [Abstract][Full Text] [Related]
7. The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.
Klapproth K; Sander S; Marinkovic D; Baumann B; Wirth T
Blood; 2009 Sep; 114(12):2448-58. PubMed ID: 19628709
[TBL] [Abstract][Full Text] [Related]
8. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
9. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
Högstrand K; Grandien A
Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
[TBL] [Abstract][Full Text] [Related]
10. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine phosphatome metabolic screen identifies TC-PTP as a positive regulator of cancer cell bioenergetics and mitochondrial dynamics.
Vinette V; Aubry I; Insull H; Uetani N; Hardy S; Tremblay ML
FASEB J; 2021 Jul; 35(7):e21708. PubMed ID: 34169549
[TBL] [Abstract][Full Text] [Related]
12. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
[TBL] [Abstract][Full Text] [Related]
13. Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-kappaB activation.
Ibarra-Sánchez MJ; Wagner J; Ong MT; Lampron C; Tremblay ML
Oncogene; 2001 Aug; 20(34):4728-39. PubMed ID: 11498795
[TBL] [Abstract][Full Text] [Related]
14. Epidermal-specific deletion of TC-PTP promotes UVB-induced epidermal cell survival through the regulation of Flk-1/JNK signaling.
Baek M; Kim M; Lim JS; Morales LD; Hernandez J; Mummidi S; Williams-Blangero S; Jang IS; Tsin AT; Kim DJ
Cell Death Dis; 2018 Jun; 9(7):730. PubMed ID: 29955047
[TBL] [Abstract][Full Text] [Related]
15. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNAs as a novel component of the Myc transcriptional network.
Winkle M; van den Berg A; Tayari M; Sietzema J; Terpstra M; Kortman G; de Jong D; Visser L; Diepstra A; Kok K; Kluiver J
FASEB J; 2015 Jun; 29(6):2338-46. PubMed ID: 25690653
[TBL] [Abstract][Full Text] [Related]
18. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.
Ott G; Rosenwald A; Campo E
Blood; 2013 Dec; 122(24):3884-91. PubMed ID: 24009228
[TBL] [Abstract][Full Text] [Related]
19. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Hoellein A; Fallahi M; Schoeffmann S; Steidle S; Schaub FX; Rudelius M; Laitinen I; Nilsson L; Goga A; Peschel C; Nilsson JA; Cleveland JL; Keller U
Blood; 2014 Sep; 124(13):2081-90. PubMed ID: 25143484
[TBL] [Abstract][Full Text] [Related]
20. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
